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When profiling metabolites, there are two general
experimental paradigms: untargeted studies at the omic
scale and targeted studies which usually focus on a
much smaller subset of compounds. Although untar-
geted studies have become increasingly fashionable and
are often perceived to be the cutting edge, it is import-
ant to recognize that they have limitations and are not
always the better experiment. In theory, an untargeted
analysis profiles all of the same metabolites as a targeted
analysis, plus more. So why is more not always better?
We will frame our consideration in the words of
pioneering computer scientist Alan Perlis: “Fools ignore
complexity. Pragmatists suffer it. Some can avoid it.
Geniuses remove it.” [1].
“Fools ignore complexity.”
Indeed, untargeted metabolomic datasets are exceedingly
complex. When applying a mass spectrometry-based plat-
form, biological samples typically generate tens of thou-
sands of signals per experiment. Even with state-of-the-art
technologies, the majority of these signals cannot be anno-
tated. Some signals are challenging to annotate because
they are experimental artifacts, while others correspond to
metabolites whose structure, function, and pathway re-
main unknown [2]. Without annotation, it is challenging
to ascribe global meaning to the datasets. For example, it
is precarious to compare the global metabolism of two
samples on the basis of the percentage of signals changing
because this percentage is highly dependent upon the
number of artifacts.
“Pragmatists suffer it.”
Despite its challenges, untargeted metabolomics is the
workflow of choice for some research applications, such
as identifying biomarkers of disease. In these applications,
researchers do not have a biochemical hypothesis prior to
beginning the analysis and generally only attempt to
identify metabolomic signals that are potentially diagnos-
tic of the condition being studied. A convincing example
of the power of untargeted metabolomics to identify
serum markers of non-small-cell lung cancer was recently
published in the Journal of Clinical Oncology. Wikoff et al.
found that the concentration of diacetylspermine increases
approximately twofold in the blood collected from
patients 6 months before diagnosis [3]. Untargeted meta-
bolomics is also well suited for other types of unbiased
screening applications. In Cancer and Metabolism, for
instance, Gelman et al. reported an application of untar-
geted metabolomics to find metabolic products of the
oncometabolite 2-hydroxyglutarate [4].
“Some can avoid it.”
The targeted analysis of metabolites provides data that
are simpler to interpret compared to data from untar-
geted studies. Additionally, there is a tradeoff between
the number of analytes measured by mass spectrometry
and the quality of the measurement (Fig. 1). Untargeted
metabolomics provides data on a larger number of com-
pounds, but the data are less quantitatively reliable.
Thus, if an investigator has a research question that can
be answered with a targeted analysis, that is the recom-
mended experiment. As a brief anecdotal example, we
recently performed untargeted metabolomics in collab-
oration with another group at Washington University.
After spending nearly a year running samples and
performing data analysis, we discovered that our collab-
orators’ question could be answered directly by measur-
ing a single metabolite. Instead of collaborating, our
colleagues realized that they could more reliably meas-
ure the metabolite of interest by using a relatively inex-
pensive immunoassay in their own laboratory. As this
account highlights, more is not always better. In their
Cancer and Metabolism review, Salamanca-Cardona
et al. discuss some other examples of when more is not
better. They highlight how “targeted” hyperpolarized
magnetic resonance imaging technologies can provide
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specific insights into cancer metabolism in vivo (such as
pH, redox state, and tumor necrosis) [5].
“Geniuses remove it.”
Great progress has been made over the last decade to
improve the robustness of the mass spectrometry-based
metabolomic platform and to facilitate the associated data
processing. Instruments are becoming more quantitatively
reliable, databases are expanding, software is advancing,
computational approaches to assess flux are evolving, and
informatic strategies to integrate gene expression data are
being developed. Some of these advances are reviewed in
Cancer and Metabolism by Markert et al. in “Mathemat-
ical Models of Cancer Metabolism” and in “Integration of
Omics: More than the Sum of its Parts” by Buescher et al.
[6, 7]. The objective is not only to reduce complexity but
also to increase accessibility so that integrated omic exper-
iments can be performed by scientists without extensive
technical expertise.
This leaves us with an interesting question: should
untargeted metabolomics be reserved as a last resort
when no other experimental approaches can solve the
problem of interest? We suggest that the answer is
yes. However, the problems that metabolomic tech-
nologies uniquely position us to solve are of excep-
tional importance to the field of cancer metabolism
and, in this sense, represent the next frontier.
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Fig. 1 Schematic of tradeoff between number of metabolites
detected and the quality at which they are measured in mass
spectrometry-based metabolomics
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